Chain Drug Review - Abbott to submit Synthroid NDA
Abbott Laboratories plans to submit an NDA for Synthroid (levothyroxine sodium, USP), a treatment for hypothyroidism. The company recently obtained rights to the product through its acquisition of BASF Pharma, which includes Knoll Pharmaceutical Co.
Related Results
Bioequivalence of generic Synthroid questionedSynthroid - Shorts - Brief ArticleBioequivalence of Synthroid, generic questionedFDA says no abrupt withdrawal for SynthroidFDA takes issue with Synthroid promotion
COPYRIGHT 2001 Racher Press, Inc.
COPYRIGHT 2008 Gale, Cengage Learning
